Fabio A. Schutz

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 766 citations · Full text

Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy

Joaquim Bellmunt, Ronan Fougeray, Jacob Rosenberg et al. · Annals of Oncology · 2013 · 177 citations · Full text

Urology, Genitourinary Cancer, Medicine +4

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Laurence Albigès et al. · New England Journal of Medicine · 2023 · 142 citations · Full text

Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Katherine M. Krajewski, Mengye Guo, Annick D. Van den Abbeele et al. · European Urology · 2011 · 112 citations

Urology, Oncologic Imaging, Genitourinary Cancer +11

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Katriina Peltola et al. · New England Journal of Medicine · 2024 · 111 citations